Director Key Accounts, GRAIL INC
Harry Hayter brings 25 years of pharmaceutical and molecular diagnostic experience to organizations looking to develop products and solutions dedicated to bringing innovation in precision medicine to the healthcare marketplace. Grail’s mission is to detect cancer early, when it can be cured. In addition, Harry is focused on providing a comprehensive view into how healthcare stakeholders can implement strategies that allow participation in bringing data, real-world evidence and a value-based approach to the delivery of care. Most recently, Harry was a VP, Commercial Markets for Tempus, a healthcare software and analytics company that is building the world’s largest library of molecular and clinical data allowing us to power a machine-learning operating system that empowers physicians to make real-time, data-driven decisions for their cancer patients. Prior to that Harry worked in Market Access for Foundation Medicine, Inc. and several Specialty Pharmaceutical Manufacturers.